References
- FletcherMJUptonJTaylor-FishwickJCOPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age populationBMC Public Health20111161221806798
- ManninoDMBramanSThe epidemiology and economics of chronic obstructive pulmonary diseaseProc Am Thorac Soc20074750250617878461
- HalbertRJNatoliJLGanoABadamgaravEBuistASManninoDMGlobal burden of COPD: systematic review and meta-analysisEur Respir J200628352353216611654
- NgTPNitiMFonesCYapKBTanWCCo-morbid association of depression and COPD: a population-based studyRespir Med2009103689590119136238
- FosterTSMillerJDMartonJPCaloyerasJPRussellMWMenzinJAssessment of the economic burden of COPD in the US: a review and synthesis of the literatureCOPD20063421121817361502
- GOLD: Global initiative for chronic obstructive lung diseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2011 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdfAccessed November 23, 2012
- Gruffydd-JonesKLoveridgeCThe 2010 NICE COPD Guidelines: how do they compare with the GOLD guidelines?Prim Care Respir J201120219920421437566
- FromerLCooperCBA review of the GOLD guidelines for the diagnosis and treatment of patients with COPDInt J Clin Pract20086281219123618547365
- TashkinDPFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res20101114921034447
- CazzolaMCalzettaLMateraMGß(2) -adrenoceptor agonists: current and future directionBr J Pharmacol2011163141721232045
- MehtaRHardesKCahnASafety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 Inhalation Powder, a new long-acting muscarinic antagonist, in healthy adults [abstract]Eur Respir J2011a38Suppl 5723s
- CahnALovickRNewlandsASafety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects [abstract]Eur Resp J201138Suppl 55723s
- MehtaRNewlandsAKelleherDPreeceACahnACraterGSafety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPDEur Respir J201138Suppl 55138s
- DonohueJAnzuetoABrooksJMehtaRKalbergCCraterGA randomized, double-blind, dose-ranging study of the novel LAMA GSK573719 in patients with COPDRespir Med2012106797097922498110
- DecramerMMaltaisFFeldmanGBronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsRespir Physiol Neurobiol2013185239339923026438
- KempsfordRNorrisVSiedererSVilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulm Pharmacol Ther201326225626423232038
- ProcopiouPABarrettVJBevanNJSynthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachJ Med Chem201053114522453020462258
- FeldmanGWalkerRRBrooksJMehtaRCraterG28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialPulm Pharmacol Ther201225646547122955035
- KelleherDLMehtaRSJean-FrancoisBMSafety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trialPLoS ONE2012712e5071623284643
- US Food and Drug AdministrationGuidance for Industry Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations Draft GuidanceSilver SpringUS Food and Drug Administration2012 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdfAccessed November 23, 2012
- World Medical AssociationWorld Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human SubjectsSeoul59th WMA General Assembly2008 Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdfAccessed November 23, 2012
- GD Searle LLCCalan (verapamil hydrochloride) [Package insert]New YorkGD Searle LLC, Division of Pfizer Inc2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018817s024lbl.pdfAccessed November 23, 2012
- SalpeterSRCardiovascular safety of beta(2)-andrenoceptor agonist use in patients with obstructive airway disease: a systematic reviewDrugs Aging200421640541415084142
- SovaniMPWhaleCITattersfieldAEA benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary diseaseDrug Saf2004271068971515350154